By: Catherine Marfin, University of Texas Health Science Center at Houston From: medicalxpress.com A peptide that successfully targeted and killed metastatic cancer cells in mice may open the door to developing more efficient ways to detect and treat metastatic breast cancer in humans, UTHealth Houston researchers have discovered. The research was published in Molecular Therapy Oncology and led by Mikhail …
Long-Term Physical Decline After Breast Cancer Therapy
By: Maurie Markman, MD From: medscape.com Clearly, it is well recognized, well established, and not controversial that chemotherapy and hormone therapy improve survival in breast cancer. Whether you’re looking at this in the metastatic setting in advanced disease or in the adjuvant setting, studies over multiple decades have clearly demonstrated improved survival when, of course, the therapy is given based …
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
By: Alexandra Gerlach From: pharmacytimes.com Key Takeaways ADCs target specific tumor antigens, enhancing therapeutic windows and efficacy, with HER2 and TROP-2 as key targets in breast cancer. HER2-targeting ADCs, T-DM1 and T-DXd, have shown significant benefits in early and metastatic breast cancer, improving survival and response rates. TROP-2-targeting ADCs, SG and Dato-DXd, are approved for metastatic breast cancer, showing efficacy …
Integrative Therapy and Nurse Navigation Reduce Treatment Side Effects for 75% of Black Breast Cancer Patients; 85% Report Lower Distress
Leading breast cancer nonprofits Unite for HER and TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA) presented new and critical research addressing health disparities, entitled “A New Comprehensive IntegrativeCare and Navigation Model for Enhancing Outcomes for Black Breast Cancer Patients: Evidence from the Care for HER Program” at the 2025 San Antonio Breast Cancer Symposium. The Care for HER Program, presented …
De-Escalating Bone-Modifying Therapy Safe, Effective in Metastatic Breast Cancer
By: Mike Bassett From: medpagetoday.com Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be safe in prostate cancer, a randomized trial showed. After at least 2 years of BMA therapy, de-escalating treatment to once every 24 weeks was noninferior to …
Experts call for change of heart on hormone replacement therapy after breast cancer
By: University College London From: medicalxpress.com Breast cancer survivors with severe menopausal symptoms should be supported to make an informed decision about whether to have hormone replacement therapy or not, according to an interdisciplinary panel of experts including researchers from UCL. The study, published in Menopause, provides the most comprehensive review to date on the use of hormone replacement therapy …
Leading cancer societies update guideline on post-mastectomy radiation therapy
From: ASCO Three leading national cancer organizations today issued an updated guideline on post-mastectomy radiation therapy (PMRT) for physicians treating patients with breast cancer. The recommendations outline when PMRT is appropriate based on new evidence and evolving clinical practice, and they highlight best practices for delivering radiation after breast removal surgery in a multidisciplinary, patient-centered setting. The American Society for …
How to Give Subsequent Therapy for Older Patients With Breast Cancer on CDK4/6 Inhibitors
By: Courtney Moore, APRN, FNP-C, OCN From: oncnursingnews.com When moving past the first line of treatment for older patients with hormone receptor (HR)–positive metastatic breast cancer due to adverse events (AEs) associated with CDK4/6 inhibitors, the patient’s whole clinical profile should be considered, said Courtney Moore, APRN, FNP-C, OCN. After a Case-Based Roundtable with Oncology Nursing News, Moore explained that …
T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer
By: Roman Fabbricatore From: .cancernetwork.com The FDA has granted fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) breakthrough therapy designation as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer, according to a news release from the drug’s developer, Daiichi-Sankyo.1 Based on results from the phase 3 DESTINY-Breast09 trial (NCT04784715), the agency’s decision follows data presented during a late-breaking oral …
FDA Grants Breakthrough Therapy Designation to Frontline T-DXd Plus Pertuzumab in HER2+ Metastatic Breast Cancer
By: Chris Ryan From: onclive.com he FDA has granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab for the first-line treatment of adult patients with HER2-positive unresectable or metastatic breast cancer. The designation was supported by data from the phase 3 DESTINY-Breast09 trial (NCT04784715). “This breakthrough therapy designation provides further recognition of the potential benefit of …